Journal of Gerontological Nursing

NEWS UPDATE 

ANTI-DIABETES DRUG MARKETED

Abstract

Kalamazoo, MI. - Micronase Tablets (glyburide), the first new oral antidiabetes medication in the United States in 18 years, soon will be available nationwide.

Micronase Tablets, which can be used once a day, are indicated as an adjunct to diet to lower blood sugar levels in patients with non-insulindependent diabetes (type II) whose elevated blood sugar levels cannot be satisfactorily controlled by diet alone. There are approximately nine million people afflicted with type II diabetes.

Micronase Tablets are not indicated for patients with insulin-dependent diabetes (type I).

Because glyburide can be used in smaller doses than oral anti-diabetes agents previously available in the U.S., Micronase Tablets are relatively small and easy to swallow.

Glyburide is unique because it is eliminated through both urine and bile (approximately 50 percent by each route). Oral anti-diabetes products previously available in the U.S. are excreted primarily in patient's urine.…

Kalamazoo, MI. - Micronase Tablets (glyburide), the first new oral antidiabetes medication in the United States in 18 years, soon will be available nationwide.

Micronase Tablets, which can be used once a day, are indicated as an adjunct to diet to lower blood sugar levels in patients with non-insulindependent diabetes (type II) whose elevated blood sugar levels cannot be satisfactorily controlled by diet alone. There are approximately nine million people afflicted with type II diabetes.

Micronase Tablets are not indicated for patients with insulin-dependent diabetes (type I).

Because glyburide can be used in smaller doses than oral anti-diabetes agents previously available in the U.S., Micronase Tablets are relatively small and easy to swallow.

Glyburide is unique because it is eliminated through both urine and bile (approximately 50 percent by each route). Oral anti-diabetes products previously available in the U.S. are excreted primarily in patient's urine.

10.3928/0098-9134-19840801-09

Sign up to receive

Journal E-contents